Citations

Clear

331 citation(s) found for "Hayes, DF".

Improvement in Functioning and Psychological Distress in Adolescents With Postural Orthostatic Tachycardia Syndrome Following Interdisciplinary Treatment
Bruce, Barbara K. , Harrison, Tracy E. , Bee, Susan, Luedtke, Connie A. , Porter, Co-burn J., Hayes, Sarah , Allman, Daniel A., Ale, Chelsea M. , Weiss, Karen E. , Bee, Susan M, Fischer, Philip R. , Hayes, Sarah E

Mayo Clinic

Clinical Pediatrics | March 16, 2016 | Volume: 55 | Issue: 14 | Pages: 1300-1304

10.1177/0009922816638663 | PMID 26983448 Get It

Significant functional impairment and psychological distress have been observed in adolescent patients with postural orthostatic tachycardia syndrome (POTS). Interdisciplinary rehabilitation programs have been shown to be beneficial in the treatment of chronic pain in adults and adolescents. Only preliminary data have examined interdisciplinary rehabilitation efforts in patients with POTS. This study evaluated the impact of an interdisciplinary rehabilitation program on the functional impairment and psychological distress in 33 adolescents diagnosed with POTS. Patients included in the study were adolescents ages 11 to 18 diagnosed with POTS. Measures completed at admission and discharge from the program included the Functional Disability Index, Center for Epidemiological Studies–Depression–Child scale, and the Pain Catastrophizing Scale for Children. After participation in the 3-week program, adolescents with POTS demonstrated a significant increase in overall functional ability and significant reductions in depression and catastrophizing.
Spontaneous coronary artery dissection and its association with heritable connective tissue disorders
Negrotto, Sara , Kirmani, Salman , Deyle, David R. , Gulati, Rajiv , Olson, Timothy M. , Negrotto, Sara M, Tweet, Marysia S. , Henkin, Stanislav , Hayes, Sharonne N. , Olson, Timothy M

Mayo Clinic

Heart | February 14, 2016 | Volume: 102 | Issue: 11 | Pages: 876-881

10.1136/heartjnl-2015-308645 | PMID 26864667 Get It

Objective Spontaneous coronary artery dissection (SCAD) is an under-recognised but important cause of myocardial infarction and sudden cardiac death. We sought to determine the role of medical and molecular genetic screening for connective tissue disorders in patients with SCAD. Methods We performed a single-centre retrospective descriptive analysis of patients with spontaneous coronary artery disease who had undergone medical genetics evaluation 1984–2014 (n=116). The presence or absence of traits suggestive of heritable connective tissue disease was extracted. Genetic testing for connective tissue disorders and/or aortopathies, if performed, is also reported. Results Of the 116 patients (mean age 44.2 years, 94.8% women and 41.4% with non-coronary fibromuscular dysplasia (FMD)), 59 patients underwent genetic testing, of whom 3 (5.1%) received a diagnosis of connective tissue disorder: a 50-year-old man with Marfan syndrome; a 43-year-old woman with vascular Ehlers–Danlos syndrome and FMD; and a 45-year-old woman with vascular Ehlers–Danlos syndrome. An additional 12 patients (20.3%) had variants of unknown significance, none of which was thought to be a definite disease-causing mutation based on in silico analyses. Conclusions Only a minority of patients with SCAD who undergo genetic evaluation have a likely pathogenic mutation identified on gene panel testing. Even fewer exhibit clinical features of connective tissue disorder. These findings underscore the need for further studies to elucidate the molecular mechanisms of SCAD.
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma
Tricoli, James V. , Blair, Donald G., Anders, Carey K. , Bleyer, W. Archie, Boardman, Lisa A., Khan, Javed , Hayes‐Lattin, Brandon , Merchant, Melinda S., Seibel, Nita L. , Thurin, Magdalena , Boardman, Lisa A., Kummar, Shivaani , Hunger, Stephen P. , Willman, Cheryl L.

Mayo Clinic

Cancer | February 5, 2016 | Volume: 122 | Issue: 7 | Pages: 1017-1028

10.1002/cncr.29871 | PMID 26849082 Get It

Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic characteristics, resulting in differences in clinical and treatment resistance behaviors. This report from the biologic component of the jointly sponsored National Cancer Institute and LiveStrong Foundation workshop entitled “Next Steps in Adolescent and Young Adult Oncology” summarizes the current status of biologic and translational research progress for 5 AYA cancers; colorectal cancer breast cancer, acute lymphoblastic leukemia, melanoma, and sarcoma. Conclusions from this meeting included the need for basic biologic, genomic, and model development for AYA cancers as well as translational research studies to elucidate any fundamental differences between pediatric, AYA, and adult cancers. The biologic questions for future research are whether there are mutational or signaling pathway differences (for example, between adult and AYA colorectal cancer) that can be clinically exploited to develop novel therapies for treating AYA cancers and to develop companion diagnostics. Cancer 2016;122:1017–1028. © 2016 American Cancer Society
Pregnancy and Parental Leave During Graduate Medical Education
Blair, Janis E. , Mayer, Anita P. , Caubet, Suzanne L., Norby, Suzanne M. , O’Connor, Mary I. , Hayes, Sharonne N.

Mayo Clinic

Academic Medicine | November 25, 2015 | Volume: 91 | Issue: 7 | Pages: 972-978

10.1097/acm.0000000000001006 | PMID 26606722 Get It

Purpose To understand the pregnancy, childbirth, and parental leave plans and experiences of trainees in multiple graduate medical education (GME) programs at a single institution. Method In 2013, the authors developed and deployed a voluntary, Internet-based survey of trainees in 269 residency and fellowship programs across the three sites of the Mayo School of Graduate Medical Education. The survey assessed pregnancy-related issues, including use of relevant institutional policies, changes in work due to pregnancy, and activities during pregnancy and parental leave. The authors analyzed the responses to make comparisons across groups. Results Forty-two percent (644/1,516) of trainees responded. Less than half (264; 41%) had children, and 46 (7%) were currently pregnant (themselves or their partners). Among parents, 24 (of 73; 33%) women and 28 (of 81; 35%) men planned to have another child during their current training program, and 13 (18%) women and 14 (17%) men planned to do so during their next training program. Among nonparents, 40 (of 135; 30%) women and 36 (of 111; 32%) men planned pregnancies during their current training program, and 25 (19%) women and 14 (13%) men planned pregnancies during their next training program. Of respondents eligible for parental leave, 81 (of 83; 98%) women and 89 (of 101; 88%) men had used it. Conclusions Approximately 40% of respondents planned to have children during their GME training; most will require family leave and institutional support. GME programs should pursue policies and practices to minimize the effects of these leaves on their workforce.
Another Report of Familial Spontaneous Coronary Artery Dissection—Reply
Goel, Kashish , Tweet, Marysia S. , Hayes, Sharonne N.

Mayo Clinic

JAMA Internal Medicine | October 5, 2015 | Volume: 175 | Issue: 10 | Pages: 1721

10.1001/jamainternmed.2015.3830 | PMID 26436744 Get It

Abstract 5489: A genome-wide association study identifies novel loci associated with taxane-related sensory neuropathy in breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221)
Sucheston‐Campbell, Lara E. , Budd, G. Thomas, Stram, D. O., Haiman, C.A., Albain, Kathy S. , Hayes, Daniel F. , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Livingston, Robert B., Sheng, Xin , Clay‐Gilmour, Alyssa , Barlow, William E. , Li, Yan , Zirpoli, Gary , Yao, Song , Hershman, Dawn L. , Moore, Halle C. F. , Isaacs, Claudine , Gralow, Julie R. , Hortobágyi, Gabriel N. , Kroetz, Deanna L. , Ambrosone, Christine B.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 5489-5489

10.1158/1538-7445.am2015-5489 Get It

Abstract Introduction: The use of multi-drug regimens, including taxanes (T), has increased survival for breast cancer patients. However, T-induced neuropathy, one of the most common side effects, cannot be predicted, prevented or effectively treated. Using genome wide analyses (GWA), we sought to identify common genetic variants that infer susceptibility to clinical and self-reported neuropathy. Methods: Women with high risk breast cancer were enrolled in SWOG 0221, a trial of dosing schedules for AC and T. Genotyping was performed using the Illumina 1M chip and SNPs examined in relation to CTCAE grade 3 and 4 neurotoxicity and self-reported symptoms (FACT-TAXANE) among women providing blood samples. Significant associations were tested for replication in CALGB40101. Results: Among 1269 European Americans (EA) and 139 African Americans (AA) in S0221, there were 147 and 31 grade 3+ neuropathies, respectively. In CALGB40101, grade 3 toxicity was less frequent (59/855 EA and 15/117 AA). In S0221 EA patients, loci on chromosomes 7, 10, 16 and 17 showed associations with grades 3 and 4 neuropathy at p<5×10e-06, with the most significant genetic association on chromosome 17, rs910920, p = 6.8×10e-08, odds ratio (OR) = 0.44 (95% confidence interval (CI), 0.32-0.61); this SNP is a cis eQTL, thought likely to affect transcription factor binding and linked to expression of VPS53 in lymphoblastoid cell lines. While the rs910920 association was specific to EA, the A allele in rs1858826 on chromosome 7 was associated with reduced odds of neuropathy in both EA (p = 7×10e-07) and AA (p = .02) groups. The S0221 associations at p<5×10e-06 did not replicate in CALGB40101. A subset of patients (n = 677 EA and n = 42 AA) completed the FACT-TAXANE. The most significant associations with this neuropathy phenotype (p<5×10e-07) were on chromosomes 2 (rs4267555 and rs4443044) and 3 (rs2421468). Of the 168 SNPs tested for association with neuropathy in previous studies, rs1695 in GSTP1 (p = 0.0009) and rs228591 in ATM (p = 0.0006), showed some evidence of association with FACT-TAXANE scores; the latter SNP was significant at p = .005 in ordinal regression analysis of neuropathy grades 0-4 in CALGB40101. None of these SNPs were significantly associated with grade 3 CTCAE neuropathy at p<.05, nor were the top CTCAE associations in relation to FACT-TAXANE scores. Replication of the most significant S0221 FACT-TAXANE findings in CALGB40101 is ongoing. Conclusions: Failure to replicate S0221 in CALGB40101, and the lack of coherence between self-report and clinical grade in S0221 could be attributable to differences in trial designs as well as differences in defining a complex phenotype. Larger homogeneous trials with similar dosing and criteria for defining neuropathy are needed to assess the relationship of genetics and the neuropathy symptom spectrum. Citation Format: Lara Sucheston-Campbell, Alyssa Clay, William E. Barlow, G Thomas Budd, Dan Stram, Chris Haiman, Li Yan, Gary Zirpoli, Song Yao, Dawn Hershman, Kathy S. Albain, Daniel F. Hayes, Halle Moore, Timothy J. Hobday, James A. Stewart, Claudine Isaacs, Muhammad Salim, Julie R. Gralow, Gabriel N. Hortobagyi, Robert B. Livingston, Xin Sheng, Deanna L. Kroetz, Christine B. Ambrosone. A genome-wide association study identifies novel loci associated with taxane-related sensory neuropathy in breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5489. doi:10.1158/1538-7445.AM2015-5489
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Poznak, Catherine Van , Somerfield, Mark R. , Bast, Robert C. , Cristofanilli, Massimo , González-Angulo, Ana M. , Hicks, David G., Hill, Elizabeth G. , Liu, Minetta C. , Lucas, Wanda, Mennel, Robert, Symmans, W. Fraser , Hayes, Daniel F. , Harris, Lyndsay N. , Van Poznak, Catherine, Mayer, Ingrid A. , Mennel, Robert G, Symmans, William F, Goetz, Matthew P. , Bast, Robert C , Symmans, W Fraser , Cristofanilli, Massimo

Mayo Clinic

Journal of Clinical Oncology | July 20, 2015 | Volume: 33 | Issue: 24 | Pages: 2695-2704

10.1200/jco.2015.61.1459 | PMID 26195705 Get It

Purpose To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective–retrospective studies, and prospective comparative observational studies published from 2006 through September 2014. Results The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective–retrospective studies that evaluated the clinical utility of biomarkers. Recommendations In patients with accessible metastases, biopsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, and HER2 status should be offered, but evidence is lacking to determine whether changing anticancer treatment on the basis of change in receptor status affects clinical outcomes. With discordance of results between primary and metastatic tissues, the Panel consensus is to use preferentially the estrogen receptor, progesterone receptor, and HER2 status of the metastasis to direct therapy if supported by the clinical scenario and patient's goals for care. Carcinoembryonic antigen, cancer antigen 15-3, and cancer antigen 27-29 may be used as adjunctive assessments, but not alone, to contribute to decisions regarding therapy. Recommendations for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel informal consensus in the absence of studies designed to evaluate the clinical utility of the markers. As such, it is also reasonable for clinicians to not use these markers as adjunctive assessments.
Association between history of psychosis and cardiovascular disease in bipolar disorder
Prieto, Miguel L. , Sutor, Bruce, Kung, Simon , Cuéllar‐Barboza, Alfredo B. , Ösby, Urban, Chauhan, Mohit , Westman, Jeanette , Geske, Jennifer R. , Colby, Colin , Ryu, Euijung , Frye, Mark A. , Bobo, William V. , Colby, Colin L., McElroy, Susan L. , Hayes, Sharonne N. , Fuentes, Manuel Enrique , Crow, Scott J. , Biernacka, Joanna M. , Cuellar-Barboza, Alfredo , Geske, Jennifer , Chauhan, Mohit

Mayo Clinic

Bipolar Disorders | June 11, 2015 | Volume: 17 | Issue: 5 | Pages: 518-527

10.1111/bdi.12302 | PMID 26062406 Get It

ObjectivesTo determine whether clinical features of bipolar disorder, such as history of psychosis, and cardiovascular disease (CVD) risk factors contribute to a higher risk of CVD among patients with bipolar disorder.MethodsThis cross‐sectional study included a sample of 988 patients with bipolar I or bipolar II disorder or schizoaffective bipolar type confirmed by the Structured Clinical Interview for DSM‐IV‐TR disorders (SCID). Medical comorbidity burden was quantified utilizing the Cumulative Illness Severity Rating Scale (CIRS). This 13‐item organ‐based scale includes cardiac disease severity quantification. Confirmed by medical record review, patients who scored 1 (current mild or past significant problem) or higher in the cardiac item were compared by logistic regression to patients who scored 0 (no impairment), adjusting for CVD risk factors that were selected using a backwards stepwise approach or were obtained from the literature.ResultsIn a multivariate model, age [odds ratio (OR) = 3.03, 95% confidence interval (CI): 1.66–5.54, p < 0.0001], hypertension (OR = 2.43, 95% CI: 1.69–3.55, p < 0.0001), and history of psychosis (OR = 1.48, 95% CI: 1.03–2.13, p = 0.03) were associated with CVD. When CVD risk factors from the literature were added to the analysis, age (OR = 3.19, 95% CI: 1.67–6.10, p = 0.0005) and hypertension (OR = 2.46, 95% CI: 1.61–3.76, p < 0.01) remained significant, with psychosis being at the trend level (OR = 1.43, 95% CI: 0.96–2.13, p = 0.08).ConclusionsThe phenotype of psychotic bipolar disorder may reflect higher illness severity with associated cardiac comorbidity. Further studies are encouraged to clarify the effect of the disease burden (i.e., depression), lifestyle, and treatment interventions (i.e., atypical antipsychotics) on this risk association.
Patient Activity and Survival Following Implantable Cardioverter‐Defibrillator Implantation: The ALTITUDE Activity Study
Kramer, Daniel B. , Mitchell, Susan L., Jones, Paul W. , Normand, Sharon‐Lise T. , Hayes, David L. , Reynolds, Matthew R. , Monteiro, João P.

Mayo Clinic

Journal of the American Heart Association | May 16, 2015 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/jaha.115.001775 | PMID 25979902 Get It

Background Physical activity data are collected automatically by implantable cardioverter‐defibrillators ( ICD s). Though these data potentially provide a quantifiable and easily accessible measure of functional status, its relationship with survival has not been well studied. Methods and Results Patients enrolled in the Boston Scientific LATITUDE remote monitoring system from 2008 to 2012 with ICD s were eligible. Remote monitoring data were used to calculate mean daily activity at baseline (30 to 60 days after implantation), and longitudinally. Cox regression was used to examine the association between survival and increments of 30 minutes/day in both (1) mean baseline activity and (2) time‐varying activity, with both adjusted for demographic and device characteristics. A total of 98 437 patients were followed for a median of 2.2 years (mean age of 67.7±13.1 years; 71.7% male). Mean baseline daily activity was 107.5±66.2 minutes/day. The proportion of patients surviving after 4 years was significantly higher among those in the most versus least active quintile of mean baseline activity (90.5% vs. 50.0%; log‐rank P value, <0.001). Lower mean baseline activity (i.e., incremental difference of 30‐minutes/day) was independently associated with a higher risk of death (adjusted hazard ratio [ AHR ], 1.44; 95% confidence interval [ CI ], 1.427 to 1.462). Time‐varying activity was similarly associated with a higher risk of death ( AHR , 1.48; 95% CI , 1.451 to 1.508), indicating that a patient having 30 minutes per day less activity in a given month has a 48% increased hazard for death when compared to a similar patient in the same month. Conclusions Patient activity measured by ICD s strongly correlates with survival following ICD implantation.
Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk
Gong, Jian , Peters, Ulrike , Chang‐Claude, Jenny , Slattery, Martha L. , Locke, Adam E. , Kahali, Bratati , Justice, Anne E. , Pers, Tune H. , Gallinger, Steven , Hayes, Richard B. , Caan, Bette J. , Ogino, Shuji , Berndt, Sonja I. , Casey, Graham , Haile, Robert W. , Du, Mengmeng , Harrison, Tabitha A. , Thornquist, Mark, Duggan, David , Lindor, Noralane M. , Seminara, Daniela, Song, Mingyang , Wu, Kana , Thibodeau, Stephen N. , Win, Aung Ko , Jenkins, Mark A. , Potter, John D. , Hoffmeister, Michael , Brenner, Hermann , Thrift, Aaron P. , Rudolph, Anja , Chan, Andrew T. , Baron, John A. , Ogino, Shuji , Chanock, Stephen Jacob , Marchand, Loı̈c Le , Cotterchio, Michelle , Hopper, John L. , Ulrich, Cornelia M. , Newcomb, Polly A. , White, Emily E. , Hsu, Li , Campbell, Peter T. , Win, Aung K , Hoffmeister, Michael , Jenkins, Mark A , Haile, Robert W , Harrison, Tabitha A , Potter, John D , Brenner, Hermann , Song, Mingyang , Hayes, Richard B , Caan, Bette J

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 14, 2015 | Volume: 24 | Issue: 7 | Pages: 1024-1031

10.1158/1055-9965.epi-14-1309 | PMID 25976416 Get It

Abstract Background: High body mass index (BMI) is consistently linked to increased risk of colorectal cancer for men, whereas the association is less clear for women. As risk estimates from observational studies may be biased and/or confounded, we conducted a Mendelian randomization study to estimate the causal association between BMI and colorectal cancer. Methods: We used data from 10,226 colorectal cancer cases and 10,286 controls of European ancestry. The Mendelian randomization analysis used a weighted genetic risk score, derived from 77 genome-wide association study–identified variants associated with higher BMI, as an instrumental variable (IV). We compared the IV odds ratio (IV-OR) with the OR obtained using a conventional covariate-adjusted analysis. Results: Individuals carrying greater numbers of BMI-increasing alleles had higher colorectal cancer risk [per weighted allele OR, 1.31; 95% confidence interval (CI), 1.10–1.57]. Our IV estimation results support the hypothesis that genetically influenced BMI is directly associated with risk for colorectal cancer (IV-OR per 5 kg/m2, 1.50; 95% CI, 1.13–2.01). In the sex-specific IV analyses higher BMI was associated with higher risk of colorectal cancer among women (IV-OR per 5 kg/m2, 1.82; 95% CI, 1.26–2.61). For men, genetically influenced BMI was not associated with colorectal cancer (IV-OR per 5 kg/m2, 1.18; 95% CI, 0.73–1.92). Conclusions: High BMI was associated with increased colorectal cancer risk for women. Whether abdominal obesity, rather than overall obesity, is a more important risk factor for men requires further investigation. Impact: Overall, conventional epidemiologic and Mendelian randomization studies suggest a strong association between obesity and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 24(7); 1024–31. ©2015 AACR.